Roth Capital Predicts CervoMed's Q1 Earnings (NASDAQ:CRVO)

CervoMed Inc. (NASDAQ:CRVO - Free Report) - Roth Capital issued their Q1 2026 EPS estimates for CervoMed in a report released on Tuesday, March 18th. Roth Capital analyst B. Pachaiyappan anticipates that the company will post earnings per share of ($0.52) for the quarter. Roth Capital currently has a "Strong-Buy" rating on the stock. The consensus estimate for CervoMed's current full-year earnings is ($1.88) per share. Roth Capital also issued estimates for CervoMed's Q2 2026 earnings at ($0.60) EPS, Q3 2026 earnings at ($0.70) EPS, Q4 2026 earnings at ($0.90) EPS and FY2026 earnings at ($2.76) EPS.

Several other equities research analysts have also recently commented on the stock. D. Boral Capital reiterated a "buy" rating and set a $10.00 price target on shares of CervoMed in a research report on Monday, March 17th. Canaccord Genuity Group lifted their target price on shares of CervoMed from $12.00 to $21.00 and gave the stock a "buy" rating in a report on Tuesday, March 18th. Chardan Capital raised CervoMed from a "neutral" rating to a "buy" rating and set a $14.00 price target on the stock in a research note on Thursday, March 13th. HC Wainwright cut CervoMed from a "buy" rating to a "neutral" rating in a research note on Tuesday, December 17th. Finally, Roth Mkm upped their price objective on CervoMed from $15.00 to $20.00 and gave the company a "buy" rating in a report on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, CervoMed has a consensus rating of "Moderate Buy" and an average price target of $27.50.

Remove Ads

CervoMed Stock Performance

NASDAQ:CRVO traded up $2.73 on Wednesday, hitting $14.29. 7,288,342 shares of the stock were exchanged, compared to its average volume of 1,218,899. CervoMed has a 52 week low of $1.80 and a 52 week high of $25.92. The stock has a market capitalization of $88.17 million, a price-to-earnings ratio of -7.04 and a beta of 1.84. The company's 50-day moving average price is $3.30 and its 200 day moving average price is $7.81.

CervoMed (NASDAQ:CRVO - Get Free Report) last released its earnings results on Monday, March 17th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.13). CervoMed had a negative net margin of 118.68% and a negative return on equity of 44.11%. The firm had revenue of $2.16 million during the quarter, compared to analyst estimates of $1.51 million.

Institutional Investors Weigh In On CervoMed

Several large investors have recently modified their holdings of CRVO. FMR LLC bought a new stake in CervoMed during the 3rd quarter worth approximately $56,000. Barclays PLC boosted its holdings in shares of CervoMed by 323.6% in the third quarter. Barclays PLC now owns 7,748 shares of the company's stock valued at $113,000 after buying an additional 5,919 shares during the period. Virtu Financial LLC bought a new stake in shares of CervoMed during the fourth quarter worth $26,000. DRW Securities LLC acquired a new stake in shares of CervoMed during the fourth quarter worth $30,000. Finally, Mariner LLC acquired a new stake in shares of CervoMed during the fourth quarter worth $30,000. 25.15% of the stock is currently owned by institutional investors.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.